Alivus Life Sciences Limited

Alivus Life Sciences disclosed an in-person one-on-one investor/analyst meeting with SBI Mutual Fund in Mumbai on August 12, 2026. The disclosure was made pursuant to SEBI LODR Regulation 30, informin

Alivus Life Sciences disclosed an investor/analyst group meeting scheduled for August 12, 2026, in Mumbai. The disclosure is a regulatory requirement under SEBI LODR Regulations, ensuring compliance w

Alivus Life Sciences reported Q1 FY27 revenue of INR640 crore, a 6.4% YoY growth, driven by a 26.5% surge in non-GPL business. EBITDA margin expanded 650 bps YoY to 36.6%, supported by favorable produ